FLOWSENSE

FlowSense Medical, founded in 2009 in Misgav, Israel, developed continuous fluid monitoring systems for critical care settings. The company was established by the investment firm The Trendlines Group, which acquired the assets that formed the basis of the company. D. Todd Dollinger, the Chairman and CEO of The Trendlines Group, also served as the chairman of FlowSense.

The company's key product was the URINFO2000, an automatic urine monitoring system that uses patented optical sensing technology to provide continuous, real-time data on a patient's urine output. This system was designed to help clinicians optimize fluid management and provide early detection of acute kidney injury (AKI), a condition that affects a significant percentage of hospitalized and critical care patients. The URINFO 2000 aimed to replace labor-intensive manual urine meters, offering more timely data for intervention. In December 2011, FlowSense signed a five-year collaboration agreement with Philips Healthcare to integrate the URINFLO 2000's data with Philips' patient monitors.

FlowSense Medical was listed on the Tel Aviv Stock Exchange (TASE) in 2010. In September 2013, the company was acquired by the global healthcare company Baxter International for $9.5 million, including liabilities. Prior to the acquisition, FlowSense had begun selling its products in Europe, the US, Israel, and China.

Keywords: fluid monitoring, urine output, critical care, acute kidney injury, medical devices, patient monitoring, renal care, optical sensing, Baxter, The Trendlines Group, URINFO2000, fluid management, nephrology, real-time monitoring, hospital devices, medical technology, automated monitoring